

Letter from the Editor

It has been a terrific year under the stewardship of Taylor & Francis. Input and guidance from the Editorial Board continues to improve and enhance the scientific quality of the published manuscripts and recognition of the journal. Expert reviews from over 400 scientists are recognized in this issue. Thank you reviewers! The reviewers continue to freely support the scientific mission of the journal by publishing only those original research manuscripts having high impact. Of the manuscripts received in 2005, 44% were rejected through this rigorous peer review process. This has resulted in a 40% increase in the impact factor from 2003, now at 0.917. We are very pleased with this significant increase and continue to reinforce the impact that the peer review process has on the quality of the manuscripts being published. The manuscripts published in Volume 31 were submitted

from 31 countries, with the most papers coming from China, United States, India, Germany, South Korea, France, Canada and Italy. I am pleased to welcome several new members to the Editorial Board, including Dr. David R. Taft (Long Island University), Dr. Paul W. S. Heng (National University of Singapore) and Dr. Alf Lamprecht (University of Franche-Comte). These gentlemen are well published and established in their respective fields, and *Drug Development and Industrial Pharmacy* will benefit greatly from their participation.

I invite you to submit your research manuscripts to *Drug Development and Industrial Pharmacy*! Please submit by email to ddc@submit.taylorandfrancis.com.

Thank you.

Bill Williams
Editor

Copyright of Drug Development & Industrial Pharmacy is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.